FDA News: Approvals, Adcomms, Complete Response Letters and Guidances

One red lottery winner or rare disease, multi-level personification, power, reverse search, secret sample, special spy, close-up. Company leader

Rare diseases

Through flux and fluidity, FDA keeps coming back to rare disease

Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.

July 8, 2026

6 min read

Heather McKenzie

Manufacturing

Amgen recalls almost 1 million bottles of heart failure drug over quality issue

July 8, 2026

1 min read

Nick Paul Taylor

Podcast

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

July 8, 2026

1 min read

Jef Akst

Approvals

Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod

July 7, 2026

2 min read

Annalee Armstrong

Opinion

The FDA must put biotech at its center or continue to cede early research to China

July 6, 2026

4 min read

Kendalle Burlin O’Connell

FDA

Despite chaos and churn, FDA decisions hold mostly steady in H1 2026

July 6, 2026

8 min read

Tristan Manalac

Editorial

Biotech’s China problem: An issue of national security or economic value for the US?

July 2, 2026

6 min read

Jef Akst

FEATURED STORIES

3D. rocket soaring. Different rockets fly high and stand out. different from others, concept startup idea, new generation, faster work better

Huntington’s disease

Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

June 30, 2026

4 min read

Heather McKenzie

Business meeting concept as a group united together as a partnership symbol of strength.

Duchenne muscular dystrophy

Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy

The FDA plans to hold an advisory committee meeting to discuss Capricor Therapeutics’ application for deramiocel, which the agency rejected last July. The news surprised CEO Linda Marbán, who told BioSpace the FDA has not communicated any issues of concern with the company’s resubmitted application.

June 26, 2026

4 min read

Heather McKenzie

Solution problem concept. Man walking on tightrope. Life coaching, transformation idea. Brainstorming in business. Vector illustration

Opinion

The hidden cost of FDA unpredictability

When the variance can’t be modeled, even disciplined biotech investors stop deploying. Here’s the cheapest fix for biotech’s investability problem.

June 26, 2026

6 min read

David Crean

Subscribe to ClinicaSpace

Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday

THE LATEST

Policy

Biopharma Update on the Novel Coronavirus: June 15

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.

June 15, 2020

3 min read

BioSpace Editorial Staff

FDA

FDA Greenlight’s Viela Bio’s Uplizna for Rare Neuroinflammatory Autoimmune Disorder

The FDA approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive. About 80% of all NMOSD patients test positive for anti-AQP4 antibodies.

June 12, 2020

3 min read

Mark Terry